JPRN-jRCTs072220028
Recruiting
Phase 2
Development and feasibility study of the treatment of movement disorders with transcranial magnetic stimulation and transcranial direct current stimulation. - treatment of movement disorders with TMS and tDCS.
Etoh Seiji0 sites30 target enrollmentJuly 25, 2022
Conditionscentral nervous system dysorders
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- central nervous system dysorders
- Sponsor
- Etoh Seiji
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Movement disorders due to central nervous system disorders
Exclusion Criteria
- •Patients with cardiac pacemakers, implantable defibrillators or implantable neurostimulators.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
A prospective feasibility study on the treatment of gastrointestinal leakage by the use of combination of covered nitinol stent and negative pressure wound treatmentK22.3K63.1Perforation of oesophagusPerforation of intestine (nontraumatic)DRKS00016048Klinik für Viszeral-, Tumor-, Transplantations- und Gefäßchirurgie, Klinikum Köln-Merheim30
Active, Not Recruiting
N/A
Clinical and pharmacological feasibility study with 2B3-101 in patients with breast cancer and leptomeningeal metastasesEUCTR2012-005096-13-NLthe Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AvL)
Not Yet Recruiting
Phase 2
Clinical and pharmacological feasibility study with 2B3-101 in patients with breast cancer and leptomeningeal metastasesleptomeningeal metastases from breast cancermetastases in brain membranes from breast cancer1000629110041543NL-OMON39893Antoni van Leeuwenhoek Ziekenhuis6
Completed
N/A
Feasibility study for a novel and clinically useful MRI sequence for imaging myelin in MS patientsloss coordinationmultiple sclerosis10012303NL-OMON41522Vrije Universiteit Medisch Centrum120
Active, Not Recruiting
Phase 2
Study to evaluate treatment efficacy by monitoring minimal residual disease in an early breast cancer populatioEarly breast cancerCancerISRCTN50261938Medica Scientia Innovation Research, S.L. (MEDSIR)1,260